These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 15671527

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M.
    Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling.
    Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, Hammann BD, Armatis P, Kanashiro CA.
    Eur J Cancer; 2005 Nov 01; 41(17):2735-44. PubMed ID: 16291086
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL.
    Prostate; 2002 Aug 01; 52(3):173-82. PubMed ID: 12111694
    [Abstract] [Full Text] [Related]

  • 9. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.
    de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Krenning EP, de Jong M.
    J Nucl Med; 2007 Jan 01; 48(1):88-93. PubMed ID: 17204703
    [Abstract] [Full Text] [Related]

  • 10. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
    Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL.
    Int J Oncol; 2007 Apr 01; 30(4):1019-28. PubMed ID: 17332943
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
    Kiaris H, Schally AV, Sun B, Armatis P, Groot K.
    Oncogene; 1999 Nov 25; 18(50):7168-73. PubMed ID: 10597318
    [Abstract] [Full Text] [Related]

  • 12. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A, Schally AV, Zarandi M, Heinrich E, Groot K, Havt A, Kanashiro CA, Varga JL, Halmos G.
    Prostate; 2007 Sep 01; 67(12):1339-53. PubMed ID: 17624923
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A, Schally AV, Rick FG, Varga JL, Baker B, Zarandi M, Halmos G.
    Prostate; 2012 Apr 01; 72(5):555-65. PubMed ID: 21796649
    [Abstract] [Full Text] [Related]

  • 14. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV.
    Prostate; 1997 Aug 01; 32(3):164-72. PubMed ID: 9254895
    [Abstract] [Full Text] [Related]

  • 15. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
    Szepeshazi K, Schally AV, Rick FG, Block NL, Vidaurre I, Halmos G, Szalontay L.
    Anticancer Drugs; 2012 Oct 01; 23(9):906-13. PubMed ID: 22926257
    [Abstract] [Full Text] [Related]

  • 16. A potent bombesin receptor antagonist inhibits bombesin-stimulated growth of mouse colon cancer cells in vitro: absence of autocrine effects.
    Narayan S, Spindel ER, Rubin NH, Singh P.
    Cell Growth Differ; 1992 Feb 01; 3(2):111-8. PubMed ID: 1323998
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
    Qin Y, Ertl T, Cai RZ, Halmos G, Schally AV.
    Cancer Res; 1994 Feb 15; 54(4):1035-41. PubMed ID: 8313359
    [Abstract] [Full Text] [Related]

  • 18. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling.
    Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL.
    Int J Cancer; 2004 Nov 20; 112(4):570-6. PubMed ID: 15382037
    [Abstract] [Full Text] [Related]

  • 19. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 20. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z, Schally AV, Plonowski A, Czompoly T, Csernus B, Varga JL.
    Prostate; 2001 Aug 01; 48(3):188-99. PubMed ID: 11494334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.